Pro-atherogenic activation of A7r5 cells induced by the oxLDL/β2GPI/anti-β2GPI complex

TING WANG*, HANG OUYANG*, HONG ZHOU, LONGFEI XIA, XIAOYAN WANG and TING WANG

Jiangsu Key Laboratory of Medicine Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China

Received March 15, 2018; Accepted July 30, 2018

DOI: 10.3892/ijmm.2018.3805

Abstract. A previous study has revealed that oxidized low-density lipoprotein (oxLDL)/β2-glycoprotein I (β2GPI)/anti-β2-glycoprotein I (anti-β2GPI), an immune complex, is able to activate the Toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB) inflammatory signaling pathway in macrophages, and consequently enhance foam cell formation and the secretion of prothrombin activators. However, the effects of the oxLDL/β2GPI/anti-β2GPI complex on vascular smooth muscle cells have yet to be investigated. The present study investigated whether the oxLDL/β2GPI/anti-β2GPI complex was able to reinforce the pro-atherogenic activities of a rat thoracic aorta smooth muscle cell line (A7r5) and examined the underlying molecular mechanisms. The results revealed that the oxLDL/β2GPI/anti-β2GPI complex treatment significantly (P<0.05 vs. the media, oxLDL, oxLDL/β2GPI and β2GPI/anti-β2GPI groups) enhanced the pro-atherogenic activation of A7r5 cells, including intracellular lipid loading, Acyl-coenzyme A cholesterol acyltransferase mRNA expression, migration, matrix metalloproteinase-9 and monocyte chemoattractant protein 1 secretion, all via TLR4. In addition, the expression of TLR4 and the phosphorylation of NF-κB p65, p38 and ERK1/2 were also upregulated in oxLDL/β2GPI/anti-β2GPI complex-treated A7r5 cells. Pre-treatment with TAK-242, a TLR4 inhibitor, was able to partly attenuate the oxLDL/β2GPI/anti-β2GPI complex-induced phosphorylation of NF-κB p65; however, it had no effect on the phosphorylation of extracellular regulated kinase 1/2 (ERK1/2) and p38. Meanwhile, the NF-κB p65 inhibitor ammonium pyrrolidinedithiocarbamate and the ERK1/2 inhibitor U0126, but not the p38 inhibitor SB203580, were able to block oxLDL/β2GPI/anti-β2GPI complex-induced foam cell formation and migration in A7r5 cells. Hence, it was demonstrated that the oxLDL/β2GPI/anti-β2GPI complex is able to enhance the lipid uptake, migration and active molecule secretion of A7r5 cells via TLR4, and finally deteriorate atherosclerosis plaques. Additionally, it was demonstrated that oxLDL/β2GPI/anti-β2GPI complex-induced foam cell formation and migration may be partly mediated by the TLR4/NF-κB signaling pathway and that ERK1/2 may also participate in the process.

Introduction

As a complex and chronic inflammatory disease and the main cause of cardiovascular failure, myocardial infarction and stroke, atherosclerosis (AS) is characterized by narrowed arteries, atheromatous plaque formation and destabilization (1). It has been demonstrated that AS is aggravated in autoimmune disorders, including antiphospholipid syndrome (APS) and systemic lupus erythematosus, implying the necessary role of autoimmunity in the mechanism of atherosclerotic progression (2,3).

APS is a systemic autoimmune disease manifested by hypercoagulable states, thromboembolic events and recurrent miscarriage in the presence of antiphospholipid antibodies (aPL), including anti-β2-glycoprotein I antibodies (anti-β2GPI), antiphosphatidylserine antibodies and lupus anticoagulants (4,5). Previous evidence has revealed that the high titer of clinically relevant anti-β2GPI antibodies in the plasma of patients with APS is highly associated with APS-associated vasculopathies and other clinical manifestations (6). As the main antigenic target of aPL, β2GPI is a protein consisting of...
326 amino acid residues and composed of five complementary control domains known as domains I to V. Domains I and IV of β2GPI have been reported to function as antigen epitopes recognized by antibodies, while domain V has a binding region for negatively charged phospholipids including cardioprotein apoE and oxidized low-density lipoprotein (oxLDL) (7,8). It is widely recognized that oxLDL accumulation in cells of atherosclerotic plaques serves a pivotal pathogenic role in the development of AS (9). OxLDL has proinflammatory and immunological effects that may result in lipid metabolic disturbance and vascular cell dysfunction (10). In 1999, β2GPI was revealed to co-localize with cluster of differentiation 4-positive lymphocytes and oxidized LDL in human atherosclerotic plaques, suggesting that β2GPI and anti-β2GPI may participate in the development of thrombosis, particularly in arterial thrombosis (atherosclerosis) (11). In addition, the levels of oxLDL/β2GPI complex in plasma are notably increased in patients with diseases characterized by cardiovascular complications including systemic autoimmune diseases, diabetes and renal disorders, indicating that oxLDL/β2GPI is an atherogenic auto-antigen (12,13). Clinical evidence has revealed that the immunoglobulin G (IgG) immune complex containing oxLDL and β2GPI serves a pathogenic role in the development of thrombosis (14). The coexistence of a stable oxLDL/β2GPI complex and autoantibodies (anti-β2GPI, anti-oxLDL and anti-oxLDL/β2GPI) against the complex have been detected in patients with APS (15,16), suggesting the potential of the formation of an oxLDL/β2GPI/antibodies complex which may be implicated in the atherogenic pathogenesis of AS. In 1997, Hasunuma et al (17) demonstrated that a complex composed of oxLDL and β2GPI is able to be recognized by anti-β2GPI antibodies derived from an in vivo model of APS. In addition, Kobayashi et al (18), Hasunuma et al (17) and Xu et al (19) have verified that the co-existence of β2GPI and anti-β2GPI IgG may substantially enhance the uptake of oxLDL by macrophages. Therefore it was hypothesized that the oxLDL/β2GPI/anti-β2GPI complex, the combination of the oxLDL/β2GPI complex and anti-β2GPI, is the circulating immune complex that exerts a pro-atherogenic effect, which has been validated by a number of published studies to a certain extent (3,17-22). Similarly, the effect of the oxLDL/β2GPI/anti-β2GPI complex on the formation of an atherosclerosis plaque is an interesting topic and may be worth investigating to verify this hypothesis.

Vascular smooth muscle cell (VSMC) is the main cell type involved in the pathogenesis of AS and is closely associated with disease progression due to its interaction with lipoproteins (23). VSMCs exhibit phenotypic and functional plasticity in order to respond to vascular injury (23,24). In the case of vessel damage, VSMCs are able to switch from the quiescent ‘contractile’ phenotype to the ‘synthetic’ phenotype (23,24). This change is accompanied by a loss of VSMC markers, an increased capacity for cell proliferation and the migration and secretion of various proinflammatory mediators (24). In contrast to the ‘contractile’ phenotype which is filled with myofilaments in the cytoplasm, the ‘synthetic’ phenotype contains a well-developed rough endoplasmic reticulum, which may contribute to the secretion of proinflammatory molecules (24). VSMCs undergoing a phenotype change may additionally acquire macrophage markers and properties, including the induction of macrophage-specific markers, increased lipid uptake and the ability to present antigens (23,24). It is widely recognized that a heightened inflammatory state serves an essential role in the progression of plaque formation (25,26). Toll-like receptor-4 (TLR4) is a type I trans-membrane pattern recognition receptor which has a critical role in initiating inflammation and particularly participating in immune system activation (27,28). TLR4 has been demonstrated to be involved in the development of AS, particularly at the early stages of the disease (27-30). Nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs) are key signaling molecules for inflammation and immune regulation in atherosclerosis and are able to mediate the signal transduction pathway of TLRs including TLR4 (31,32).

In vitro and in vivo evidence has implicated the potential function of TLR4 and/or NF-κB and/or MAPKs in a series of physiological changes and inflammatory responses, including foam cell formation, proatherogenic inflammatory cytokines secretion, proliferation and migration (19,21,29-32). However, the detailed association of these transduction signals in VSMCs has not been clearly identified. A full understanding of the behavior of VSMCs in AS with autoimmune backgrounds is critical for the prevention and treatment of arterial thrombosis.

One previous study has demonstrated that the oxLDL/β2GPI/anti-β2GPI complex may enhance the conversion of macrophages into foam cells and increase the expression of monocyte chemoattractant protein 1 (MCP-1) and tissue factor (TF) via the TLR4/NF-κB pathway (19,21). Considering the different properties between macrophages and VSMCs, the effects of the oxLDL/β2GPI/anti-β2GPI complex on VSMCs and the underlying molecular mechanisms require further investigation. In the present study, the effects of the oxLDL/β2GPI/anti-β2GPI complex on the lipid uptake, migration and active molecules secretion of A7r5 cells were investigated, in addition to the potential transduction pathway.

Materials and methods

Cell culture. The A7r5 cell line was obtained from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). The cells were maintained in DMEM-F12 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a humidified incubator with 5% CO2 and routinely sub-cultured at subconfluence (>90%). Cells were serum starved for 16 h prior to stimulation with oxLDL (50 µg/ml; Biomedical Technologies, Inc., Stoughton, MA, USA), oxLDL (50 µg/ml)/β2GPI (100 µg/ml; United States Biological, Salem, MA, USA), β2GPI (100 µg/ml)/anti-β2GPI (100 µg/ml; Chemicon International, Temecula, CA, USA), oxLDL (50 µg/ml)/β2GPI (100 µg/ml)/anti-β2GPI (100 µg/ml); lipopolysaccharide (LPS; 500 ng/ml; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 37°C for 12, 24 or 48 h. The complex of oxLDL/β2GPI and oxLDL/β2GPI/anti-β2GPI were prepared by incubating oxLDL (50 µg/ml) with β2GPI (100 µg/ml) at 37°C for 16 h as previously described (16). The concentration of the other reagents was determined...
by pre-experiments and previous studies (16,19,21). For the interfering corresponding signaling pathway, prior to the aforementioned treatments, the cells were pre-treated at 37°C with 5 µM TLR4 inhibitor TAK-242 (Invitrogen; Thermo Fisher Scientific, Inc.), 20 µM NF-κB inhibitor ammonium pyrrolidinedithiocarbamate (PDTC; Sigma-Aldrich; Merck KGaA), 10 µM p38 inhibitor SB203580 (Sigma-Aldrich; Merck KGaA) and 10 µM extracellular regulated kinase 1/2 (ERK1/2) inhibitor U0126 (Selleck chemicals, Houston, TX, USA) for 2 h. The absence of endotoxin contamination (<0.03 EU/ml) in all reagents (except for LPS) was verified using a Limulus amebocyte lysate kit (Pyrotell; Associates of Cape Cod, Inc., Saint Jean Drive, MA, USA) according to the manufacturers' protocol. Briefly, all reagents (except for LPS) were mixed with pyrochrome at a ratio of 1:1. Then, in a microplate, the pyrochrome-sample mixture was incubated at 37°C for 30 min (100 µl/well) and read at 550 nm in an optical reader (Gene Company, Ltd., Hong Kong, China). The endotoxin concentrations were then calculated.

Oil Red O staining and quantitative analysis of foam cell formation. The oil red O stock solution was prepared by dissolving 0.5 g oil red O powder (Sigma-Aldrich; Merck KGaA) in 100 ml isopropanol, diluted to 60% with deionized water and filtered as the working solution. A7r5 cells were fixed in 4% paraformaldehyde for 20 min at room temperature (RT). Subsequent to washing with PBS three times, the cells were stained with oil red O working solution at 37°C for 30 min and washed with 60% ethanol for several seconds to remove background staining. Following counterstaining with 10% hematoxylin at RT for 10 min, the stained cells were photographed and evaluated using an inverted optical microscope (Olympus Corporation, Tokyo, Japan) at a magnification of x200. The foam cells were discerned by observing oil red O stained lipid droplets in the cytoplasm.

The foam cell formation was quantitatively analyzed by detecting total intracellular oil red O. In brief, intracellular oil red O was extracted with 100% isopropanol at RT for 30 min, and absorbance of the extraction at 520 nm was measured using a kinetic microplate reader (Gene company, Ltd., Hong Kong, China). The optical density (OD) was in proportion to the number of positive cells. The cutoff value for a 'high' OD value was calculated by the mean ± standard deviation of the media control (DMEM-F12 medium).

Quantification of intracellular cholesterol content. Intracellular total cholesterol (TC) and free cholesterol (FC) of A7r5 cells were determined using the Total cholesterol assay kit (cat no. E1015) and Free cholesterol assay kit (cat no. E1016) from Applygen Technologies, Inc. (Beijing, China). In brief, A7r5 cells subsequent to the aforementioned treatments were collected in a centrifuge tube and intracellular lipids were extracted by adding 100 µl isopropanol alcohol. Following sonification, the mixtures were centrifuged for 5 min at 2,000 x g at 4°C. Then, the supernatant was collected for detecting intracellular cholesterol by performing an enzymatic assay according to the manufacturer's protocol of the assay kits. The quantity of TC and FC in the cell extracts were calculated according to the standard curve. Cellular protein concentrations were determined based on a BCA assay by using a BCA Protein Assay kit (cat no. P0011; Beyotime Institute of Biotechnology, Shanghai, China) according to the manufacturer's protocol. The results were then expressed as microgram of cholesterol per milligram of cellular protein. The intracellular cholesterol contents (TC and FC) were normalized with a media control (DMEM-F12 medium).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. RT-qPCR was used to assess the mRNA levels of acyl-coenzyme A cholesterol acyltransferase (ACAT1), monocyte chemoattractant protein 1 (MCP-1) and matrix metalloproteinase-9 (MMP-9) following the incubation of A7r5 cells with different treatments as aforementioned. Total RNA was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) and reverse transcribed into cDNA using the HiscriptTM First-strand cDNA Synthesis kit (Vazyme, Piscataway, NJ, USA) and reverse transcribed into cDNA using the Hiscr iptTM First-strand cDNA Synthesis kit (Vazyme, Piscataway, NJ, USA) according to manufacturer's protocol for RT-qPCR analysis. The mRNA level of target genes was examined by RT-qPCR using SYBR Green I dye (Vazyme). The primers used for qRcR were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China) and their sequences were presented in Table I. The PCR assays were performed in triplicate on a Rotor-Gene 2000 Real-Time Quantitative PCR system (Corbett Life Science; Qiagen, Inc., Valencia, CA, USA). The amplification run was performed for 35 cycles under the following conditions: 95°C for 30 sec, 60°C (MMP-9) / 60°C (GAPDH) / 60°C (MCP-1) for 30 sec and 72°C for 30 sec. The semi-quantitative mRNA level of target gene to GAPDH was calculated using 2^-∆∆Ct method and normalized with a media control (DMEM-F12 medium) (33).

Wound healing assay. A wound healing assay was performed as follows: Cells were briefly seeded in 6-well plates and cultured to 95% confluence. The wound gap (100 µm) of the cell monolayer was created using a sterile 200-µl pipette tip across the diameter, following different treatments as aforementioned. Cell images were obtained immediately and again 48 h later. The images of the wound area were obtained by a light microscope (magnification, x100; Olympus Corporation). The same visual field was marked and used throughout the experiment. The total distance migrated by wounded A7r5

| Gene | Primer sequence (5’-3’) |
|------|------------------------|
| GAPDH (133 bp) | F: GACAACCTTGGATCGTGAG | R: ATGCAAGGTAGTGTCTTGG |
| ACAT1 (121 bp) | F: AAGTACGCCATCAGCTTTA | R: CCTCTTCACCA CCAAGTCTT |
| MMP-9 (356 bp) | F: CCCTGCTATTTCATTCA | R: AAACCCCATCCTTGTCACC |
| MCP-1 (356 bp) | F: TGCTGTCTACAGCAGATGCGT | R: AGAAGTGCTTGGAGTGGTTGGAC |

F: forward; R, reverse.
cells was evaluated using ImageJ software (version: 1.8.0; National Institutes of Health, Bethesda, MD, USA).

Transwell migration assay. A Transwell migration assay was performed using 8-µm pore size inserts (Corning Incorporated, Corning, NY, USA) set on 24-well plates. In brief, cell suspensions (4x10⁴ cells/well) were added to the upper chamber of the inserts in the presence of different agonists (TAK-242; PdTc; SB203580 and U0126) and serum-free DMEM-F12 medium, while the lower was filled with DFM12 medium containing 10% FBS. After 12 h incubation at 37°C, the non-migrated cells above the membrane were removed using a cotton swab. The membrane was fixed with 4% paraformaldehyde for 20 min at RT, stained with 0.5% crystal violet for 30 min at RT to identify the migrated cells, and photographed with an inverted light microscope (Olympus Corporation) at a magnification of x100. Then, the crystal violet on the membrane was dissolved in 33% acetic acid, and the OD values of the solutions at 570 nm were used to directly assess the cell migration.

Western blot analysis. To obtain total cellular proteins, cells incubated with different treatments as aforementioned were lysed in RIPA buffer (P0013K; Beyotime Institute of Biotechnology) containing 1 mM phenylmethylsulfonyl fluoride for 1 h at 4°C. The cell lysates were centrifuged at 13,800 x g for 10 min at 4°C and stored at -80°C for analysis. Cellular protein concentrations were determined using a BCA Protein Assay kit (cat no. P0011; Beyotime Institute of Biotechnology) according to the manufacturer’s protocol. An equal amount of protein (100 µg) was separated by electrophoresis using 10% sodium dodecyl sulfate-polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (PVDF; Bio-Rad Laboratories, Inc., Hercules, CA, USA). Following blocking with fresh 5% fat-free milk for 1 h at RT, PVDF membranes were incubated with the primary antibodies against polyclonal β-actin antibody (1:5,000; cat no. #AP0060; Bioworld Technology, Inc., St. Louis Park, MN, USA), monoclonal rabbit anti-rat TLR4 (1:500; cat no. #sc-76B357.1; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), monoclonal rabbit anti-rat NF-κβ p65 (1:1,000; cat no. #8242; Cell Signaling Technology, Inc., Danvers, MA, USA), monoclonal mouse anti-rat phospho-NF-κβ-p65 (1:1,000; cat no. #3033; Cell Signaling Technology, Inc.), monoclonal mouse anti-rat phospho-ERK1/2 (1:1,000; cat no. #sc-7388; Santa Cruz Biotechnology, Inc.), monoclonal mouse anti-rat phospho-p38 (1:1,000; cat no. #sc-7972; Santa Cruz Biotechnology, Inc.), monoclonal mouse anti-rat-phospho-ERK1/2 (1:1,000; cat no. #sc-514302; Santa Cruz Biotechnology, Inc.), monoclonal mouse anti-rat-phospho-p38 (1:1,000; cat no. #sc-7972; Santa Cruz Biotechnology, Inc.), monoclonal mouse anti-rat-phospho-ERK1/2 (1:1,000; cat no. #sc-166182; Santa Cruz Biotechnology, Inc.) overnight at 4°C. Following washing with PBS for 10 min three times, the membranes were then incubated with horseradish peroxidase-conjugated goat anti-rabbit (1:5,000; cat no. BS13278; BioWorld Technology, Inc.) or anti-mouse (1:5,000; cat no. #AP124F; EMD Millipore, Billerica, MA, USA) secondary antibodies for 1 h at RT. Finally, the protein bands were visualized using electrochemiluminescence detection reagents (GE Healthcare, Chicago,
IL, USA) and imaged using an ImageQuant LAS 4000 Imager and quantitated by Labwork version 4.6 (UVP, LLC, Phoenix, AZ, USA).

Enzyme-linked immunosorbent assay (ELISA). A7r5 cells were seeded at a density of 1.0x10^5/well in a 96-well plate. Subsequent to being serum-starved for 16 h, cells were treated with different stimulants as aforementioned. Cells in certain wells were pretreated with TAK-242 (5 µM) for 2 h, and MMP-9 secreted into the cell culture media was measured using MCP-1 ELISA kit (cat no. ERC113; Neobioscience Technology, Co., Ltd., Shenzhen, Guangdong, China) and MMP-9 ELISA kit (cat no. ERC 018; Neobioscience Technology, Co., Ltd.) according to the manufacturer’s protocol. The protein levels were expressed as pg/ml in cell culture media.

Statistical analysis. All experiments were performed in triplicate or quadruplicate and repeated at least 3 times. Data were expressed as the mean ± standard error of the mean. Statistical significance was examined using a Student's unpaired t-test (two tailed) for two-group comparisons and one-way analysis of variance with Dunnett’s post-test for multiple-group comparisons. Statistical evaluation was performed using SPSS statistical software package version 20.0 (IBM Corp., Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

OxLDL/β2GPI/anti-β2GPI complex promotes the lipid uptake of A7r5 cells and the involvement of TLR4. To investigate whether the oxLDL/β2GPI/anti-β2GPI complex may enhance the lipid accumulation of A7r5 cells and include the involvement of TLR4, the cells were incubated with different stimuli (media, oxLDL, oxLDL/β2GPI, β2GPI/anti-β2GPI or oxLDL/β2GPI/anti-β2GPI complex) for 48 h. Oil Red O staining and intracellular cholesteryl quantitation were performed to assess the capability of lipid uptake. As presented in Fig. 1, oxLDL was essential for the foam cell formation, as confirmed by intensive lipid droplets in the cytoplasm stained with Oil Red O and high OD values (P<0.05 vs. media group; Fig. 1B). More notably, compared with the control groups, A7r5 cells in the oxLDL/β2GPI/anti-β2GPI complex group presented a significantly greater number of lipid droplets (P<0.05 vs. oxLDL and oxLDL/β2GPI group; Fig. 1B) and increased intracellular cholesterol level (TC and FC; P<0.05 vs. oxLDL group; Fig. 1C). Furthermore, when cells were pretreated with TAK-242, which is able to specifically bind to TLR4 to interfere with the interactions between TLR4 and its adaptor molecules, the lipid accumulation of A7r5 cells in all groups containing oxLDL were partially but significantly attenuated (P<0.05 vs. the corresponding group without TAK-242 treatment; Fig. 1A-C).

Similarly, the mRNA levels of ACAT1, which is a key and exclusive enzyme involved in the synthesis of cholesteryl esters, were also significantly increased in A7r5 cells treated with oxLDL/β2GPI/anti-β2GPI complex (P<0.05 vs. media group), and this increase was partially but significantly reversed by TAK-242 pretreatment (P<0.05 vs. the corresponding group without TAK-242 treatment; Fig. 1D). These results suggest that the oxLDL/β2GPI/anti-β2GPI complex may enhance the lipid accumulation of A7r5 cells and include the involvement of TLR4, which may contribute to the progression of atherosclerosis.

Figure 2. OxLDL/β2GPI/anti-β2GPI complex induced the migration of A7r5 cells via toll-like receptor 4. A7r5 cell was pre-treated with or without TAK-242 for 2 h, then stimulated with oxLDL, oxLDL/β2GPI, β2GPI/anti-β2GPI or oxLDL/β2GPI/anti-β2GPI complex for 48 h or 12 h respectively. (A) A wound healing assay of A7r5 cells treated with different stimulants for 48 h was performed and (B) quantified. A7r5 cells were then seeded into the upper chamber of a Transwell insert. Trans-membrane cells were (C) stained with crystal violet and (D) quantified by reading the absorbance at 570 nm after 12 h. The data are expressed as the mean ± standard error of the mean (n=5 per group). *P<0.05 vs. the corresponding media group, #P<0.05 vs. the corresponding group without TAK-242 treatment. OxLDL, oxidized low-density lipoprotein; β2GPI, β2 glycoprotein I; OD, optical density.
in intracellular cholesteryl esterification, was increased more substantially in the oxLDL/β2GPI/anti-β2GPI complex group compared with the control group (P<0.05 vs. oxLDL, oxLDL/β2GPI and β2GPI/anti-β2GPI group; Fig. 1D). Additionally, the apparent inhibitory effects of TAK-242 on ACAT1 mRNA expression were also present in the oxLDL and oxLDL/β2GPI groups (P<0.05 vs. media and the corresponding group without TAK-242 treatment; Fig. 1D).

OxLDL/β2GPI/anti-β2GPI complex induced A7r5 cell migration and the involvement of TLR4. To reveal whether the oxLDL/β2GPI/anti-β2GPI complex is able to promote A7r5 cell migration via TLR4, a wound healing assay (Fig. 2A and B) and a Transwell migration assay (Fig. 2C and D) were performed to assess the cell migratory ability. The results revealed that the oxLDL/β2GPI/anti-β2GPI complex was able to substantially enhance A7r5 cell migration when compared with the control groups (P<0.05 vs. oxLDL, oxLDL/β2GPI and β2GPI/anti-β2GPI group; Fig. 2B and D). Furthermore, pre-treatment with a TLR4 inhibitor (TAK-242) partly attenuated the promotion of migration in oxLDL, oxLDL/β2GPI and oxLDL/β2GPI/anti-β2GPI complex groups (P<0.05 vs. media and the corresponding group without TAK-242 treatment), whereas the effect of β2GPI/anti-β2GPI on migration was completely blocked (P<0.05 vs. β2GPI/anti-β2GPI group without TAK-242 treatment and P>0.05 vs. media group; Fig. 2B and D).

Involvement of TLR4 in the oxLDL/β2GPI/anti-β2GPI complex upregulated pro-atherogenic molecule expression. MMP-9 is one of the major MMPs secreted by VSMCs, which is activated and upregulated in atherosclerotic lesions, contributing to the migration of VSMCs by degrading the extracellular matrix (34). MCP-1, which is synthesized by several activated vascular cells, is able recruit circulating monocytes to the plaque area and result in a greater number of foam cells forming and the aggravation of vascular inflammation (35). In the present study, the effects of the oxLDL/β2GPI/anti-β2GPI complex on the expression of MCP-1 and MMP-9 were investigated. The results revealed...
that oxLDL, oxLDL/β2GPI and β2GPI/anti-β2GPI in addition to the oxLDL/β2GPI/anti-β2GPI complex were able to increase MCP-1 and MMP-9 mRNA expression and protein secretion compared with the media control (P<0.05 vs. media; Fig. 3), and the effects of the oxLDL/β2GPI/anti-β2GPI complex were more notable compared with any other group (P<0.05 vs. oxLDL, oxLDL/β2GPI and β2GPI/anti-β2GPI group; Fig. 3). To investigate whether TLR4 was involved in mediating this process, A7r5 cells were pre-treated with TLR4 inhibitor TAK-242 prior to other treatments. The data revealed that TAK-242 was able to partly decrease the mRNA and protein expression of MCP-1 and MMP-9 in A7r5 cells treated with oxLDL, oxLDL/β2GPI, β2GPI/anti-β2GPI and oxLDL/β2GPI/anti-β2GPI complex for (A and B) 24 or (C and D) 48 h. Cell lysates were collected for analyzing (A) TLR4 expression and the phosphorylation of (B) NF-κB p65, (C) p38 and (D) ERK1/2 by western blot analysis. The data are expressed as the mean ± standard error of the mean (n=5 per group). *P<0.05 vs. the corresponding media group, #P<0.05 vs. the oxLDL/β2GPI/anti-β2GPI complex group.

Function of TLR4 in oxLDL/β2GPI/anti-β2GPI complex-stimulated phosphorylation of NF-κB and MAPKs. TLR4-mediated signal transduction has been reported to participate in VSMCs pathogenesis of AS (27,29,30,32). The results of the present study also confirmed that the oxLDL/β2GPI/anti-β2GPI complex is able to induce A7r5 cell foam cell formation, migration and active molecule secretion, which were partly mediated by TLR4. Subsequently, the effects of the oxLDL/β2GPI/anti-β2GPI complex on TLR4 expression and the phosphorylation of NF-κB and MAPKs in A7r5 cells were investigated to further clarify the participation of TLR4-mediated signal transduction in a series of pro-atherogenic phenotypes. As presented in Fig. 4A, cells treated with the oxLDL/β2GPI/anti-β2GPI complex had a significantly increased expression of TLR4 protein (P<0.05 vs. media,
levels of NF-κB p65 in oxLDL/β2GPI/anti-β2GPI complex and LPS-treated groups compared with the control group (P<0.05 vs. the corresponding group without TAK-242; Fig. 5A). LPS, the natural ligand of TLR4, is widely confirmed to trigger the downstream transduction pathway of TLR4 (36). Of note, the phosphorylation of ERK1/2 and p38 may not be attenuated by TAK-242 in oxLDL/β2GPI/anti-β2GPI complex treated group (P>0.05 vs. oxLDL/β2GPI/anti-β2GPI complex group without TAK-242; Fig. 5A) while the effects of LPS were completely blocked (P<0.05 vs. LPS group without TAK-242; Fig. 5C).

**Discussion**

AS may result in the dysfunction of vascular cells, arteries lesions and atheroma formation and is the pathological foundation of numerous cardiovascular diseases (37,38). The roles of inflammatory reactions and immune system activation in AS have been investigated in previous research (30,31,39). Growing evidence has demonstrated that AS has an autoimmune nature and autoimmunity serves an important role in atherogenesis (3,40). Accumulating evidence supports the hypothesis that the oxLDL/β2GPI/anti-β2GPI complex, a potential pro-atherogenic immune complex, is the circulating immune complex that exerts a pro-atherogenic effect in patients with AS with APS (3,17-22). The pro-atherogenic activation of macrophages induced by the oxLDL/β2GPI/anti-β2GPI complex with or without inhibitors; Fig. 5B and D). However, the effects of the oxLDL/β2GPI/anti-β2GPI complex on cells were not normalized by SB203580 (P>0.05 vs. oxLDL/β2GPI/anti-β2GPI complex group without inhibitors; Fig. 5B and D).

In the progression of AS, VSMCs exhibit phenotypic switching, including migration and foam cell formation, in response to vascular injury (24). In advanced AS plaque, the majority of foam cells displayed VSMC markers, with only 30% presenting a macrophage phenotype whereas 45% presented a VSMC phenotype, indicating that the foam cell formation of VSMCs is a fundamental process in the pathology of AS (41). Subsequent to migrating into the intima, VSMCs accumulate excessive oxLDL in the cytoplasm and transform into foam cells, which contribute to AS progression (23,24). In the
advanced stage of AS, the apoptosis and necrosis of foam cells result in the structural complexity and rupture of the atherosclerotic plaque, ultimately resulting in serious cardiovascular events (23,24). ACAT1, whose activity is present in a variety of cells and tissues, is an intracellular enzyme that converts FC into cholesteryl esters for storage in lipid droplets, promoting foam cell formation in atherosclerotic lesions (42,43). It is well-accepted that the expression of ACAT1 promotes intracellular lipid accumulation and ultimately results in foam cell formation in macrophages and smooth muscle cells (29,44). In the present study, whether the oxLDL/β2GPI/anti-β2GPI complex was able further enhance the lipid uptake capabilities of A7r5 cells compared with oxLDL alone and other control stimuli was examined; additionally, the function of TLR4 in the phagocytosis of the oxLDL/β2GPI/anti-β2GPI complex in A7r5 cells was verified. Firstly, Oil Red staining and intracellular cholesterol measurement results suggested a more aggressive effect of the oxLDL/β2GPI/anti-β2GPI complex on lipid uptake in A7r5 cells (Fig. 1A-C). The data also reveal that the oxLDL/β2GPI/anti-β2GPI complex may significantly upregulate the expression of ACAT1 mRNA, implying the involvement of ACAT1 in complex-induced foam cell formation of A7r5 cells (P<0.05 vs. oxLDL, oxLDL/β2GPI and β2GPI/anti-β2GPI group; Fig. 1D). The aberrant migration of VSMCs is regarded as a key mechanism for the development of the initial thickening and the progression of the thickened intima to an fibroatheroma or fibrous plaque (23). MMP-9 and MCP-1 are able to promote VSMC migration from the tunica media into the intima and the infiltration of macrophages, respectively, which are the earliest events in formation of arterial plaques (47,48). In the present study, the effect of the oxLDL/β2GPI/anti-β2GPI complex on migration, MMP-9 and MCP-1 secretion during the process of VSMC foam cell formation was examined. The results demonstrated that the oxLDL/β2GPI/anti-β2GPI complex further enhanced inflammatory secretion and migration, in addition to the foam cell formation of VSMCs (29,46). It is reported that TLR4 is able to facilitate oxLDL-induced inflammatory secretion and migration, in addition to the foam cell formation of VSMCs (29,46). In support of this, the results of the present study revealed that the oxLDL/β2GPI/anti-β2GPI complex-induced lipid accumulation and ACAT1 mRNA expression of A7r5 cells were partly blocked by a TLR4 inhibitor, providing evidence for the hypothesis that the oxLDL/β2GPI/anti-β2GPI complex-enhanced lipid uptake in A7r5 cells is partially mediated by TLR4, and that ACAT1 participates in the process (Fig. 1). Noteworthy, similar effects were also presented in other groups containing oxLDL, which were consistent with a previous study in which the authors demonstrated that oxLDL was able to promote foam cell formation of vascular smooth muscle cells by upregulating TLR4-mediated ACAT1 expression (29). It may be explained by the fact that oxLDL and the oxLDL/β2GPI/anti-β2GPI complex, to some degree, share a common signaling pathway in inducing the foam cell formation of VSMCs.

Figure 6. PDTC and U0126 attenuated the oxLDL/β2GPI/anti-β2GPI complex-induced foam cell formation and migration of A7r5 cells. Cells were pre-treated with or without PDTC, SB203580 and U0126 for 2 h, then stimulated with oxLDL/β2GPI/anti-β2GPI complex for 48 and 12 h. (A) Foam cells formation (B) quantified, and (C) the migration (D) quantified of A7r5 cells were presented. The data are expressed as the mean ± standard error of the mean (n=5 per group). *P<0.05 vs. corresponding media group, #P<0.05 vs. corresponding group without inhibitors treatment. OxLDL, oxidized low-density lipoprotein; β2GPI, β2 glycoprotein I; PDTC, ammonium pyrrolidinedithiocarbamate; OD, optical density.
complex was able to further potentiate the A7r5 cell migration ability and the expression of MMP-9 (Figs. 2 and 3). In addition, the oxLDL/β2GPI/anti-β2GPI complex had the strongest effect on MCP-1 expression in A7r5 cells when compared with other control groups (Fig. 3). The present study further confirmed the involvement of TLR4 in the oxLDL/β2GPI/anti-β2GPI complex-induced migration and MMP-9 and MCP-1 expression of cells through the use of TAK-242. Treatment with TAK-242 partly inhibited oxLDL, oxLDL/β2GPI and oxLDL/β2GPI/anti-β2GPI complex-induced migration, but completely inhibited the effect of β2GPI/anti-β2GPI (Figs. 2 and 3). Similarly, TLR4 inhibition partially impeded the effect of oxLDL, oxLDL/β2GPI and the oxLDL/β2GPI/anti-β2GPI complex on MMP-9 and MCP-1 expression whereas the β2GPI/anti-β2GPI-induced effect was completely diminished. However, the inhibitory effect of TAK-242 on MMP-9 and MCP-1 mRNA expression was not as notable compared with the effect on the protein secreted into the supernatant, which may be explained by post-translational modifications (Fig. 3). Altogether, these results demonstrated that the oxLDL/β2GPI/anti-β2GPI complex and oxLDL, in addition to oxLDL/β2GPI, induced migration and pro-atherogenic molecule secretion in the process of A7r5 cell foam cell formation, which were partly mediated by TLR4. In addition, the function of TLR4 in the β2GPI/anti-β2GPI-induced molecule activation was verified, which is consistent with previous results in THP-1 cells and macrophages (19,21,49).

Regarding the signaling molecules that are involved in the TLR4-modulated VSMC pro-atherogenic activation, the present study focused on the function of NF-κB and MAPKs. As aforementioned, NF-κB and MAPKs have been reported to be involved in pro-atherogenic behaviors, including foam cell formation, migration and inflammatory cytokine synthesis (19,21,29,30,32). Although still not fully elucidated, the precise signaling transduction mechanism underlying VSMC foam cell formation and migration has attracted increasing attention (29,50). Particularly, the TLR4 downstream cascade that was implicated in the effects of the oxLDL/β2GPI/anti-β2GPI complex needs to be further determined.

In order to elucidate this, TLR4 expression and the phosphorylation of NF-κB and MAPKs with or without TAK-242 were detected during treatment with the oxLDL/β2GPI/anti-β2GPI complex. It was revealed that TLR4 protein expression and the relative phosphorylation level of NF-κB p65, ERK1/2 and p38 were largely increased during stimulation with the oxLDL/β2GPI/anti-β2GPI complex and the activation of NF-κB p65 was dependent on TLR4 activation (Fig. 4A-D). Of note, the oxLDL/β2GPI/anti-β2GPI complex had no effect on the phosphorylation of JNK (data not shown) and TAK-242 was unable to decrease the effect of the oxLDL/β2GPI/anti-β2GPI complex on the activation of ERK1/2 and p38 (Fig. 5). These unanticipated observations suggest that there may be multiple receptors mediating oxLDL/β2GPI/anti-β2GPI complex-induced pro-atherogenic behaviors, including TLR2 and Fcγ receptors. Furthermore, inhibitors of NF-κB, ERK1/2 and p38 were used to verify their involvement in oxLDL/β2GPI/anti-β2GPI complex-induced VSMC phenotypic switching. It was revealed that the oxLDL/β2GPI/anti-β2GPI complex-induced foam cell formation and migration of A7r5 cells were partly impaired by PDTC and U0126, but not SB203580 (Fig. 5). These results clearly demonstrate that oxLDL/β2GPI/anti-β2GPI complex-induced A7r5 cell foam cell formation and migration are partly mediated by the TLR4/NF-κB signaling pathway and that ERK1/2 is also involved in the process.

The importance of the present study is that it is the first study, to the best of our knowledge, to certify the effect of three complexes, composed of APS-associated pathogenic anti-β2GPI, β2GPI and atherogenic oxLDL, on the lipid uptake, migration and active molecule expression of VSMCs. Although it may be concluded that oxLDL is the primary component of the oxLDL/β2GPI/anti-β2GPI complex, the effects of β2GPI and anti-β2GPI cannot be ignored. The importance of the function of β2GPI and anti-β2GPI may be demonstrated by the stronger effect of the oxLDL/β2GPI/anti-β2GPI complex compared to oxLDL alone, and the upregulated expression of ACAT1, MMP-9 and MCP-1, in addition to the enhanced migration, induced by β2GPI/anti-β2GPI (Figs. 1D, 2 and 3). However, the present study has limitations. As an intensively investigated member of the TLR family, TLR4 has a critical role in initiating inflammation and participates in VSMC activation (19,21,27,29-31). It has been reported that, different to lipid receptors, TLR4 may potentiate lipid uptake capacity indirectly by activating an inflammatory reaction (29). In the future, the detailed molecular mechanisms, including other potential receptors, including CD36, TLR2 and Fcγ, involved in the oxLDL/β2GPI/anti-β2GPI complex-induced pro-atherogenic pathogenesis process, in addition to the association between oxLDL/β2GPI/anti-β2GPI complex-induced inflammation and intracellular lipid disorders, should be further determined to clarify the results of the present study. Pro-atherosclerotic switches in VSMC phenotypes is a multi-step and complex mechanism that maybe be induced by a variety of proinflammatory stimuli (23,24,51). Hence, the effects of the oxLDL/β2GPI/anti-β2GPI complex on other pro-atherogenic activation methods of VSMCs, including phenotype change, proliferation and apoptosis, require further investigation in order to obtain a full understanding of the function of the oxLDL/β2GPI/anti-β2GPI complex in the pathology of AS.

In conclusion, the present study demonstrated that the oxLDL/β2GPI/anti-β2GPI complex was able to induce pro-atherogenic alterations in A7r5 cells, in which the TLR4/NF-κB signaling pathway and ERK1/2 are involved, contributing to the development of atherosclerotic plaque. It strongly suggests that the oxLDL/β2GPI/anti-β2GPI complex serves a pivotal role in the pro-atherogenic activities of VSMCs and provides an explanation for the clinical observation that the incidence rate of cardiovascular diseases is higher in patients with APS, in addition to a novel research direction and therapy target of AS for patients with autoimmune diseases.

**Acknowledgements**

Not applicable.

**Funding**

The present study was supported by the National Natural Science Foundation of China (grant no. 81370614) to HZ, the
Availability of data and material
All data generated or analyzed during this study are included in this published article.

Authors' contributions
TW and HZ conceived the study and designed the experiments. TW and HO performed the experiments. LX and XW collected and analyzed the experimental results. TW drafted and revised the article.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Glass CK and Witztum JL: Atherosclerosis. the road ahead. Cell 104: 503-516, 2001.
2. Amaya-Amaya J, Rojas-Villarraga A and Anaya JM: Cardiovascular disease in the apolipoprotein B100 syndrome. Lupus 23: 1288-1291, 2014.
3. Matsuura E, Atzeni F, Sarzi-Puttini P, Turiel M, Lopez LR and Nurmohamed MT: Is atherosclerosis an autoimmune disease? BMC Med 12: 47, 2014.
4. Stern C, Chamley L, Hale L, Kloss M, Speirs A and Baker HW: Antibodies to beta2 glycoprotein I are associated with intra-fertilization implantation failure as well as recurrent miscarriage: Results of a prevalence study. Fertil Steril 70: 938-944, 1998.
5. Habe K, Wada H, Matsumoto T, Ohishi K, Ikejiri M, Matsubara K, et al: Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases. Intern Med 97: 345-350, 2013.
6. Amory C, Levine SR, Brey RL, Gebrigziahber M, Tuhrim S, Tilley BC, Simpson PC, Sacco RL and Mohr JP: APASS-WARSS Collaborators: Antiphospholipid antibodies and recurrent thrombotic events: Persistence and portfolio. Cerebrovasc Dis 40: 293-300, 2015.
7. Li J, Chi Y, Liu S, Wang L, Wang R, Han X, Matsuura E and Liu Q: Recondominant variant of β2-glycoprotein I inhibits the formation of atherogenic oxLDL/β2-glycoprotein I complexes. J Clin Immunol 34: 669-676, 2014.
8. Otomo K, Amengual O, Fujieda Y, Nakagawa H, Kato M, Oku K, Horita T, Yasuda S, Matsumoto M, Nakayama KI, et al: Role of apolipoprotein B100 and oxidized low-density lipoprotein in the monocye tissue factor induction mediated by anti-β2-glycoprotein I antibodies. Lupus 25: 1288-1298, 2016.
9. Ouweeneel AB and Van Eck M: Lipoproteins as modulators of atherothrombosis, from endothelial function to primary and secondary coagulation. Vascul Pharmacol 82: 1-10, 2016.
10. Di Pietro N, Formoso G and Pandolfi A: Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. Vascul Pharmacol 84: 1-7, 2016.
11. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J and Shoenfeld Y: Immunologic localization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression. Circulation 99: 2277-2280, 1999.
12. Yu R, Yuan Y, Niu D, Song J, Liu T, Wu J and Wang J: Elevated beta2-glycoprotein I-low-density lipoprotein levels are associated with the presence of diabetic microvascular complications. J Diabetes Complications 29: 59-63, 2015.
13. Kasahara J, Kobayashi K, Maeshima Y, Yamazaki Y, Yasuda T, Matsuura E and Makino H: Clinical significance of serum oxidized low-density lipoprotein/β2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract 98: c15-c24, 2004.
14. Xu Y, Kong X, Zhou H, Zhang X, Liu J, Yan J, Xie H and Xie Y: oxLDL/β2GPI/anti-β2GPI complex induced macrophage differentiation to foam cell involving TLR4/NF-kappa B signal transduction pathway. Thromb Res 134: 384-392, 2014.
15. Matsuura E and Lopez LR: Are oxidized LDL/β2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis? Clin Dev Immunol 11: 103-111, 2004.
16. Kobayashi K, Kishi M, Atsumi T, Bertolacci ML, Makino H, Sakairi N, Yamamoto I, Yasuda T, Khamashta MA, Hughes GR, et al: Circulating oxidized LDL forms complexes with beta2-glycoprotein I: Implication as an atherogenic autoantigen. J Lipid Res 44: 716-726, 2003.
17. Hasunuma Y, Matsuura E, Makita Z, Katabira T, Nishi S and Koike T: Involvement of beta 2-glycoprotein I and anti-antioxidant antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107: 569-573, 1997.
18. Kobayashi K, Tada K, Itabe H, Ueno T, Liu PH, Tsutsuji A, Kuwana M, Yasuda T, Shoenfeld Y, de Groot PG and Matsuura E: Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 16: 929-938, 2007.
19. Xu Y, Kong X, Zhou H, Zhang X, Liu J, Yan J, Xie H and Xie Y: oxLDL/β2GPI/anti-β2GPI complex induced macrophage differentiation to foam cell involving TLR4/NF-kappa B signal transduction pathway. Thromb Res 134: 384-392, 2014.
20. Bassi N, Ghirardello I, Iaccarino L, Zampieri S, Rampudda ME, Atzeni F, Sarzi-Puttini P, Shoenfeld Y and Doria A: OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev 7: 52-58, 2008.
21. Zhang X, Xie Y, Zhou H, Xu Y, Liu J, Xie H and Yan J: Involvement of TLR4 in oxidized LDL/β2GPI/anti-β2GPI-induced transformation of macrophages to foam cells. J Atheroscler Thromb 21: 139-151, 2014.
22. Tabus I, García-Cardeña G and Owens GK: Recent insights into the cellular biology of atherosclerosis. J Cell Biol 209: 13-22, 2015.
23. Bennett MR, Sinha S and Owens GK: Vascular smooth muscle cells in atherosclerosis. Circ Res 116: 692-702, 2015.
24. Chistiakov DA, Orekhov AN and Bobryshev YV: Vascular smooth muscle cell in atherosclerosis. Acta Physiol(Oxf) 214: 33-50, 2015.
25. Hartman J and Frishman WH: Inflammation and atherosclerosis: A review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 22: 147-151, 2014.
26. Matsuura E, Lopez LR, Shoenfeld Y and Ames PR: β2-glycoprotein I and oxidative inflammation in early atherogenesis: A progression from innate to adaptive immunity? Autoimmun Rev 12: 241-249, 2012.
27. Roshan MH and Tambo A: The role of TLR2, TLR4, and TLR9 in the pathogenesis of atherosclerosis. Int J Inflam 2016: 1532832, 2016.
28. Hopkins PN: Molecular biology of atherosclerosis. Physiol Rev 93: 1317-1542, 2013.
29. Lu Y, Liu W, Liao SQ, Zhang MJ, Liu Y, Li BH, Zhou Y, Chen L, Gao CY, Li JC and Zhang LL: TLR4-mediated inflammation promotes foam cell formation of vascular smooth muscle cell by upregulating ACAT1 expression. Cell Death Dis 6: 1659, 2015.
30. Yang X, Zhang XJ, Cao JL, Liu XH, Liu ZH, Wang XQ, Chen QJ, Lin L, Shen W and Liu Y: Toll-like receptor 4 mediates inflammatory cytokine secretion in smooth muscle cells induced by oxidized low-density lipoprotein. PLoS One 9: e95935, 2014.
31. Kong F, Ye B, Cao J, Cai X, Lin L, Huang S, Huang W and Huang Z: Curcumin represses NLRP3 inflammasome activation via TLR4/MyD88/ NF-κB and P2X7R signaling in PMA-induced macrophages. Front Pharmacol 7: 369, 2016.

32. Jing Q, Xin SM, Cheng ZJ, Zhang WB, Zhang R, Qin YW and Pei G: Activation of p38 mitogen-activated protein kinase by oxidized LDL in vascular smooth muscle cells: Mediation via pertussis toxin-sensitive γ proteins and association with oxidized LDL-induced cytotoxicity. Circ Res 84: 831-839, 1999.

33. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

34. Newby AC: Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 69: 614-624, 2006.

35. Lin J, Kakkar V and Lu X: Impact of MCP-1 in atherosclerosis. Curr Pharm Des 20: 4580-4588, 2014.

36. Płociennikowska A, Hromada-Judycka A, Borzęcka K and Kwiatkowska K: Cooperation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell Mol Life Sci 72: 557-581, 2015.

37. Ross R and Glomset JA: Atherosclerosis and the arterial smooth muscle cell. Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180: 1332-1339, 1973.

38. Badimon L and Vilahur G: Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med 276: 618-632, 2014.

39. Sima P, Vannucci L and Vetvicka V: Atherosclerosis as autoimmune disease. Ann Transl Med 6: 116, 2018.

40. Tanaka N, Masuoka S, Kusunoki N, Nanki T and Kawai S: Serum resistin level and progression of atherosclerosis during glucocorticoid therapy for systemic autoimmune diseases. Metabolites 6: E28, 2016.

41. Rosenfeld ME and Ross R: Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis 10: 680-687, 1990.

42. Suckling KE and Strange EF: Role of acyl-CoA: Cholesterol acyltransferase in cellular cholesterol metabolism. J Lipid Res 26: 647-671, 1985.

43. Rudel LL, Lee RG and Cockman TL: Acyl coenzyme A: Cholesterol acyltransferase types 1 and 2: Structure and function in atherosclerosis. Curr Opin Lipidol 12: 121-127, 2001.

44. Sakashita N, Miyazaki A, Takeya M, Horiiuchi S, Chang CC, Chang TY and Takahashi K: Localization of human acyl-coenzyme A: Cholesterol acyltransferase-1 (ACAT-1) in macrophages and in various tissues. Am J Pathol 156: 227-236, 2000.

45. Dai Y, Cao Y, Zhang Z, Valluruopalli S and Mehta JL: Xanthine oxidase induces foam cell formation through LOX-1 and NLRP3 activation. Cardiovasc Drugs Ther 31: 19-27, 2017.

46. Yang J, Jian R, Yu J, Zhi X, Liao X, Yu J and Zhou P: CD73 regulates vascular smooth muscle cell functions and facilitates atherosclerotic plaque formation. IUBMB Life 67: 853-860, 2015.

47. Kim J and Ko J: Human SlZP promotes atherosclerosis via MMP-9 transcription and vascular smooth muscle cell migration. FASEB J 28: 5010-5021, 2014.

48. Chae IG, Yu MH, Im NK, Jung YT, Lee J, Chun KS and Lee IS: Effect of Rosemarinus officinalis L. on MMP-9, MCP-1 levels, and cell migration in RAW 264.7 and smooth muscle cells. J Med Food 15: 879-886, 2012.

49. Xie HX, Zhou H, Wang HB, Chen DD, Xia LF, Wang T and Yan JC: Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. Mol Immunol 53: 246-254, 2013.

50. Cheng YC, Sheen JM, Hu WL and Hung YC: Polypolynol and oxidative stress in atherosclerosis-related ischemic heart disease and stroke. Oxid Med Cell Longev 2017: 8526438, 2017.

51. Chaabane C, Coen M and Bochaton-Piallat ML: Smooth muscle cell phenotypic switch: implications for foam cell formation. Curr Opin Lipidol 25: 374-379, 2014.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.